跨性别与性别多元个体睾酮治疗中突破性出血的管理
本研究为单一三级中心回顾性病历审查,纳入96例使用睾酮性别肯定激素治疗1年后出现突破性出血的跨性别与性别多元个体。97%(93例)至少采取1种管理方法,79%(77例)经1至4次尝试后出血得到成功管理;除子宫切除术外,无任何方法显著优于无干预。作者建议根据患者目标个体化选择管理方法。
要点
- 使用睾酮1年后出现突破性出血者中,97%(93/96)采取了至少1种管理方法。
- 79%(77/96)经1至4次尝试后突破性出血得到成功管理,63%的管理尝试首次即成功。
- 除子宫切除术外,无任何管理方法显著优于无干预,作者建议根据患者目标个体化选择方法。
核心结论
- 在本研究中,药物治疗方法管理突破性出血未发现优于单纯观察。
- 在缺乏支持任何方法优越性的数据时,作者建议根据患者目标个体化选择尝试的方法。
研究设计与样本
- 经机构审查委员会批准的单一三级中心回顾性病历审查。
- 对象为使用睾酮性别肯定激素治疗1年后出现突破性出血的跨性别与性别多元个体,共96例。
- 审查病历以确定患者特征、睾酮使用情况及突破性出血管理方法。
主要发现
- 96例中97%(n=93)至少采取1种管理方法。
- 开始睾酮时平均年龄21.9岁(标准差5.4),睾酮使用时间中位数54.5个月(四分位距33.5,82)。
- 突破性出血时仅16%(n=15)正在使用月经抑制。
- 突破性出血在77例(79%)中经1至4次尝试方法后成功管理,超过一半的管理尝试(63%)首次即成功。
- 各管理方法的成功率范围为33%至100%;除子宫切除术完全成功外,无任何方法显著优于无干预。
临床怎么用
- 作者建议根据患者目标个体化选择突破性出血的管理方法,原文未据此给出具体推荐等级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While many transgender and gender diverse individuals rapidly achieve amenorrhea on testosterone, emerging data have identified that breakthrough bleeding can occur in up to one-third of individuals with long-term use. Breakthrough bleeding can worsen dysphoria and patients may seek management to reattain amenorrhea. Because of this, there is a need to assess efficacy of management approaches. OBJECTIVE: The primary aim of the study was to evaluate methods used by patients and their providers to manage breakthrough bleeding which arises after 1 year of testosterone use. Secondary aims included describing the diagnostic approaches to breakthrough bleeding, and proposing an algorithm for classification and management of breakthrough bleeding in this patient population. STUDY DESIGN: This was an institutional review board-approved single tertiary center, retrospective chart review of transgender and gender diverse individuals on testosterone gender affirming hormone therapy who experienced breakthrough bleeding after 1 year of use. Charts were reviewed to determine patient characteristics, testosterone use, and breakthrough bleeding management approaches. RESULTS: Of the 96 individuals who had been on testosterone for 1 year and experienced breakthrough bleeding, 97% (n=93) engaged in at least 1 approach to management. The mean age at initiation of testosterone was 21.9 (standard deviation 5.4) and the median duration of time on testosterone was 54.5 months (interquartile range 33.5, 82). Only 16% (n=15) were using menstrual suppression at the time of their breakthrough bleeding episode. Breakthrough bleeding was successfully managed in 77 (79%), following between 1 and 4 attempted approaches. More than half of management attempts (63%) were successful on the first try. When management approaches were analyzed independently, the range of success associated with any particular approach was between 33% and 100%. Other than hysterectomy, which was fully successful at managing breakthrough bleeding, no approach was significantly better than no intervention. This was true both for individuals who did and did not bleed with missed testosterone doses. Regardless of what approach was used, after a failed attempt, the next attempt was successful in more than half of individuals. Of the 16 who underwent hysterectomy, 1 did so in part as a first line approach to manage breakthrough bleeding. CONCLUSION: In this study, use of medical management methods was not found to be superior to observation alone in the management of breakthrough bleeding. In the absence of data supporting superiority of any method, we recommend tailoring method attempts to patients' goals.
引用
- Grimstad FW, Boskey ER, Clark RS, et al. Management of breakthrough bleeding in transgender and gender diverse individuals on testosterone. Am J Obstet Gynecol. 2024. PMID: 38876414. doi:10.1016/j.ajog.2024.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。